Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.

Authors:
Chunwan Lu Dafeng Yang John D Klement Yolonda L Colson Nicholas H Oberlies Cedric J Pearce Aaron H Colby Mark W Grinstaff Han-Fei Ding Huidong Shi Kebin Liu

J Immunother Cancer 2022 01;10(1)

Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA, USA

Background: Granzyme B is a key effector of cytotoxic T lymphocytes (CTLs), and its expression level positively correlates with the response of patients with mesothelioma to immune checkpoint inhibitor immunotherapy. Whether metabolic pathways regulate expression in CTLs is incompletely understood.

Methods: A tumor-specific CTL and tumor coculture model and a tumor-bearing mouse model were used to determine the role of glucose-6-phosphate dehydrogenase (G6PD) in CTL function and tumor immune evasion. A link between granzyme B expression and patient survival was analyzed in human patients with epithelioid mesothelioma.

Results: Mesothelioma cells alone are sufficient to activate tumor-specific CTLs and to enhance aerobic glycolysis to induce a PD-1 Gzmb CTL phenotype. However, inhibition of lactate dehydrogenase A, the key enzyme of the aerobic glycolysis pathway, has no significant effect on tumor-induced CTL activation. Tumor cells induce H3K9me3 deposition at the promoter of , the gene that encodes the rate-limiting enzyme G6PD in the pentose phosphate pathway, to downregulate expression in tumor-specific CTLs. G6PD activation increases acetyl-coenzyme A (CoA) production to increase H3K9ac deposition at the promoter and to increase expression in tumor-specific CTLs converting them from a Gzmb to a Gzmb phenotype, thus increasing CTL tumor lytic activity. Activation of G6PD increases Gzmb tumor-specific CTLs and suppresses tumor growth in tumor-bearing mice. Consistent with these findings, expression level was found to correlate with increased survival in patients with epithelioid mesothelioma.

Conclusion: G6PD is a metabolic checkpoint in tumor-activated CTLs. The H3K9me3/G6PD/acetyl-CoA/H3K9ac/Gzmb pathway is particularly important in CTL activation and immune evasion in epithelioid mesothelioma.

Download full-text PDF

 Source
http://dx.doi.org/10.1136/jitc-2021-003543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753452PMC
January 2022

Publication Analysis

Top Keywords

tumor-specific ctls
16
expression tumor-specific
12
aerobic glycolysis
8
cytotoxic lymphocytes
8
deposition promoter
8
ctl activation
8
metabolic checkpoint
8
patients epithelioid
8
immune evasion
8
ctl tumor
8
granzyme expression
8
expression level
8
expression
7
ctls
7
ctl
6
g6pd
6
tumor-specific
6
tumor
5
epithelioid mesothelioma
4
enhance aerobic
4

Keyword Occurance

Similar Publications

Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.

Authors:
Lu Lu He Zhang Yudong Zhou Jiayi Lin Weidong Gao Ting Yang Jinmei Jin Lijun Zhang Dale G Nagle Weidong Zhang Ye Wu Hongzhuan Chen Xin Luan

Theranostics 2022 24;12(7):3456-3473. Epub 2022 Apr 24.

Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

TRAF6 signaling pathway in T cells regulates anti-tumor immunity through the activation of tumor specific Th9 cells and CTLs.

Authors:
Astri Dewayani Naganori Kamiyama Nozomi Sachi Sotaro Ozaka Benjawan Saechue Shimpei Ariki Mizuki Goto Thanyakorn Chalalai Yasuhiro Soga Chiaki Fukuda Yomei Kagoshima Yoichi Maekawa Takashi Kobayashi

Biochem Biophys Res Commun 2022 Apr 29;613:26-33. Epub 2022 Apr 29.

Department of Infectious Disease Control, Faculty of Medicine, Oita University, Oita, Japan. Electronic address:

CD8 cytotoxic T lymphocytes (CTLs) and CD4 helper T (Th) cells play a critical role in protective immune responses to tumor cells. Particularly, Th9 cells exert anti-tumor activity by producing IL-9. TNF receptor (TNFR)-associated factor 6 (TRAF6) is an adaptor protein that mediates the signals from both the TNFR superfamily and Toll-like receptors (TLRs). Read More

View Article and Full-Text PDF
April 2022
Similar Publications

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8 T cells for cancer immunotherapy.

Authors:
Keunok Jung Min-Jeong Son Se-Young Lee Jeong-Ah Kim Deok-Han Ko Sojung Yoo Chul-Ho Kim Yong-Sung Kim

Mol Cancer 2022 Apr 22;21(1):102. Epub 2022 Apr 22.

Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.

Background: Redirecting pre-existing virus-specific cytotoxic CD8 T lymphocytes (CTLs) to tumors by simulating a viral infection of the tumor cells has great potential for cancer immunotherapy. However, this strategy is limited by lack of amenable method for viral antigen delivery into the cytosol of target tumors. Here, we addressed the limit by developing a CD8 T cell epitope-delivering antibody, termed a TEDbody, which was engineered to deliver a viral MHC-I epitope peptide into the cytosol of target tumor cells by fusion with a tumor-specific cytosol-penetrating antibody. Read More

View Article and Full-Text PDF
April 2022
Similar Publications

MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma.

Authors:
Kuo Jiang Qianfeng Zhang Yong Fan Jia Li Jitao Zhang Wentao Wang Jinzhu Fan Yunshan Guo Shichang Liu Dingjun Hao Yongxiang Wang Lei Wang Lequn Shan

Cell Death Discov 2022 Mar 15;8(1):117. Epub 2022 Mar 15.

Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.

The efficacy of immune checkpoint blockade (ICB) therapy depends on sufficient infiltration and activation of primed tumor-specific cytotoxic T lymphocytes (CTLs) in the tumor microenvironment. However, many tumor types, including osteosarcoma, mainly display immune-desert or immune-excluded phenotypes, which are characterized by a lack of tumor-infiltrating lymphocytes and a poor response to ICB monotherapy. Thus, novel therapeutic strategies are urgently needed to surmount these obstacles. Read More

View Article and Full-Text PDF
March 2022
Similar Publications

Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro.

Authors:
Shimpei Maruoka Toshiyasu Ojima Hiromitsu Iwamoto Junya Kitadani Hirotaka Tabata Shinta Tominaga Masahiro Katsuda Keiji Hayata Akihiro Takeuchi Hiroki Yamaue

Sci Rep 2022 02 28;12(1):3295. Epub 2022 Feb 28.

Second Department of Surgery, School of Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8510, Japan.

Significant efficacy of induced pluripotent stem cells (iPSCs) in generating DCs for cancer vaccine therapy was suggested in our previous studies. In clinical application of DC vaccine therapy, however, few DC vaccine systems have shown strong clinical response. To enhance immunogenicity in the DC vaccine, we transfected patient-derived iPSDCs with in vitro transcriptional RNA (ivtRNA), which was obtained from tumors of three patients with colorectal cancer. Read More

View Article and Full-Text PDF
February 2022
Similar Publications
}